In clinical practice, special attention is required to monitor CRS and early markers of activation (fever, tachycardia, and increase in CRP/IL-6) and, in case of association with ICI, to manage irAE according to guidelines (steroid/anti-cytokine algorithms). The gene discussed is CRP; the disease is congenital rubella syndrome.